Table 5 Antibiotic treatment of ventilator-associated tracheobronchitis
Questions | Global | SPF group | Latin American group | P valuea | OR (95% CI)a |
|---|---|---|---|---|---|
n = 288 | n = 141 | n = 147 | |||
n (%) | n (%) | n (%) | |||
All VAT patients should receive ATB treatment? | |||||
Yes | 121 (42.0) | 59 (41.8) | 62 (42.2) | 1.00 | ND |
No | 75 (26.0) | 31 (22.0) | 44 (29.9) | 0.16 | ND |
Only in patients with cardiovascular failure | 70 (24.3) | 41 (29.1) | 29 (19.7) | 0.08 | 1.6 (0.9-2.9) |
Unknown | 22 (7.6) | 10 (7.1) | 12 (8.2) | 0.90 | |
Which is the most appropriate treatment for VAT? | |||||
Broad-spectrum IV ATBs | 84 (29.2) | 37 (26.2) | 47 (32.0) | 0.34 | ND |
Narrow-spectrum IV ATBs | 20 (6.9) | 15 (10.6) | 5 (3.4) | 0.002 | 3.3 (1.1-10.9) |
Select ATBs according to MV days | 145 (50.3) | 74 (52.5) | 71 (48.3) | 0.55 | ND |
Nebulized ATBs | 6 (2.1) | 2 (1.4) | 4 (2.7) | 0.71 | ND |
Broad-spectrum IV ATBs + nebulized ATBs | 7 (2.4) | 1 (0.7) | 6 (4.1) | 0.14 | ND |
Never | 26 (9.0) | 12 (8.5) | 14 (9.5) | 0.92 | ND |
Which is the most appropriate option for treatment of VAT? | |||||
IV ATBs in monotherapy | 180 (62.5) | 99 (70.2) | 81 (55.1) | 0.01 | 1.9 (1.1-3.2) |
IV ATBs in combination | 60 (20.8) | 20 (20.6) | 31 (21.1) | 0.16 | ND |
IV ATBs + nebulized ATBs in monotherapy | 27 (9.4) | 7 (5.0) | 20 (13.6) | 0.02 | 0.3 (0.1-0.8) |
IV ATBs + nebulized ATBs in combination | 16 (5.6) | 2 (1.4) | 14 (9.5) | 0.006 | 0.1 (0.02-0.6) |
No reply Timing to start ATB treatment? | 5 (1.7) | 4 (2.8) | 1 (0.7) | 0.34 | ND |
<12 hours | 211 (73.3) | 96 (68.1) | 115 (78.2) | 0.07 | 0.5 (0.3-1.0) |
13-24 hours | 44 (15.3) | 23 (16.3) | 21 (14.3) | 0.75 | ND |
>24 hours | 24 (8.3) | 17 (12.1) | 7 (4.8) | 0.04 | 2.7 (1.01-7.5) |
Never ATB treatment | 9 (3.1) | 5 (3.5) | 4 (2.7) | 0.95 | ND |
ATB duration | |||||
7-10 days | 25 (8.7) | 7 (5.0) | 18 (12.2) | 0.04 | 0.3 (0.1-0.9) |
7-10 day but de-escalation | 167 (58.0) | 84 (59.0) | 83 (56.5) | 0.67 | ND |
14 days | 1 (0.3) | 0 | 1 (0.7) | 1.00 | ND |
Until clinical resolution | 22 (7.6) | 13 (9.2) | 9 (6.1) | 0.44 | ND |
<7 days | 71 (24.7) | 35 (24.8) | 36 (24.5) | 1.00 | ND |
No reply | 2 (0.7) | 2 (1.4) | 0 | 0.90 | ND |